Clinical trials: Mets
Peritoneal Carcinomatosis
A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets
Peritoneal carcinomatosis (PC) results from the metastasis of a primary cancer of the peritoneum (e.g., appendiceal, ovarian, uterine, colorectal, and gastric cancers) that then disseminates throughout the abdominal cavity.
- Trial name
- NCT04950166
- Testing
- pegsitacianine
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- OncoNano Medicine, Inc.
Liver Metastasis, Colorectal Neoplasms
Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases
The purpose of this study is to determine whether the Litx platform is safe and effective in the treatment of liver metastasis arising from colorectal cancer.
- Conditions
- Liver Metastasis, Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
- Trial name
- NCT00068068
- Testing
- Talaporfin sodium (LS11), LED-based light infusion device, Light emitting diodes (LED)
- Where
- 6 sites in United States, Germany
- Volunteers
- 25 people
- Sponsor
- Light Sciences LLC
Complications; Arthroplasty
The Evaluation of the METS™ Proximal Humeral System
This study is a single centre, non-randomised, post market clinical follow up examining retrospective patient data from a series of surgical cases; which involved the endoprosthetic replacement of the proximal humerus using the…
- Trial name
- NCT02774174
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- Stryker Orthopaedics
Prostate Cancer, Bone Metastases
A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer
This study is intended to test an experimental new drug called, EMD 525797 (Study Drug). This drug is not yet approved for sale and has only been tested in a small number of people to date (prior to this study starting another…
- Trial name
- NCT00958477
- Testing
- EMD 525797
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metabolic Syndrome (MetS), Inflammation
Comparing a Healthy Beef-Centric Diet to a Healthy U.S.-Style Diet on Metabolic Health Outcomes in Pre-Diabetic Adults
This randomized study will be conducted to compare the effect of a healthy beef-centric diet to a healthy U.S.-style dietary pattern on inflammation and other metabolic health outcomes in a metabolic syndrome and/or pre-diabetic…
- Conditions
- Metabolic Syndrome (MetS), Inflammation, Pre-Diabetes
- Trial name
- NCT07269847
- Testing
- Healthy Beef-Centric Diet, Healthy U.S.-Style Dietary Pattern
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- National Cattlemen's Beef Association, a contractor to the Beef Checkoff
Metastatic Liver Cancer, Ocular Melanoma
Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver
The safety and efficacy of CS-PHP-melphalan has been evaluated in a phase 3 trial conducted in the same patient population as well as using the same melphalan dosing as proposed in this study.
- Conditions
- Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma
- Trial name
- NCT01728051
- Testing
- Melphalan, Percutaneous Hepatic Perfusion
- Where
- 6 sites in United States
- Sponsor
- Delcath Systems Inc.
Lipidemia, Type 2 Diabetes (T2DM)
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as…
- Conditions
- Lipidemia, Type 2 Diabetes (T2DM), Metabolic Syndrome (MetS)
- Trial name
- RUBENS (NCT07219602)
- Testing
- obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg
- Where
- 55 sites in United States, Czechia and 2 more
- Volunteers
- 300 people
- Sponsor
- NewAmsterdam Pharma
Brain Tumor, Non Small Cell Lung Cancer
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA…
- Trial name
- LIMITLESS (NCT05317858)
- Testing
- Blood Brain Barrier Opening - Oncology, Pembrolizumab, Atezolizumab
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- InSightec
Colorectal Cancer, Colorectal Carcinoma
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
This study is a randomized multi-center trial that will assess the effect of adding Selective Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres®, to a standard chemotherapy regimen of FOLFOX as first line therapy…
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
- Trial name
- SIRFLOX (NCT00724503)
- Testing
- SIR-Spheres yttrium-90 microspheres, Systemic chemotherapy (FOLFOX)
- Where
- 111 sites in United States, Australia and 9 more
- Volunteers
- 530 people
- Sponsor
- Sirtex Medical
Infection
Post Market Clinical Follow Up Study for Evaluation of Agluna® METS
The Agluna® (antimicrobial ionic silver surface technology) is used to treat the surface of the METS (Modular Endoprosthetic Tumour System) medical devices, in order to reduce the risk of post surgical infections after…
- Trial name
- NCT02779504
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- Stryker Orthopaedics
Colorectal Cancer Metastatic
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
This study is a randomized, multi-center study that will compare the efficacy and safety of selective internal radiation therapy (SIRT) using SIR-Spheres microspheres plus a standard chemotherapy regimen of FOLFOX6m versus…
- Trial name
- FOXFIREGlobal (NCT01721954)
- Testing
- FOLFOX6m, SIR-Spheres microspheres
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 209 people
- Sponsor
- Sirtex Medical
Melanoma and Brain Metastases
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
This is a global, multi-centre, open-label, study of GSK2118436 conducted in up to 30 evaluable subjects with resectable, BRAF V600E or V600K mutation-positive metastatic melanoma to the brain.
- Trial name
- NCT01978236
- Testing
- Dabrafenib 150 mg, Trametinib 2.0 mg
- Where
- 3 sites in United States, Australia
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Bone Metastases
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
The primary objective is to compare the diagnostic performance of 18F- Fluoride PET/CT scanning to that of conventional bone scanning for detecting cancer that has spread to the bone (bone metastasis).
- Trial name
- NCT00882609
- Testing
- Bone Scan: F18-Fluoride PET/CT or TC-MDP
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 550 people
- Sponsor
- American College of Radiology - Image Metrix
Metastases, Neoplasm, Carcinoma, Non-Small-Cell Lung
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
Brain metastases from solid tumors are diagnosed in more than 300,000 patients annually. Nonsmall cell lung cancer accounts for the majority of CNS mets.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms
- Trial name
- NCT00034697
- Testing
- temozolomide
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain Metastases
GliaSite 1-3 Mets Study
This study has been designed to compile information on the efficacy of the GliaSite RTS combined with radiosurgery in the treatment of newly diagnosed metastatic brain tumors.
- Trial name
- NCT00589212
- Testing
- GliaSite Radiation Therapy System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Hologic, Inc.
Metabolic Syndrome, Type 2 Diabetes
LUPS-Lipids and Glucose Under Prospective Surveillance
Prospective, non-randomized cohort study to analyse genetic variations, dietary patterns, perceived stress and anxiety and early changes in lipid metabolism leading to the metabolic syndrome and type 2 diabetes
- Trial name
- LUPS (NCT01313156)
- Where
- 2 sites in Germany
- Volunteers
- 1,962 people, healthy volunteers welcome
- Sponsor
- Asklepios proresearch
Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Open label, multi-centre, Phase Ia/b adaptive design study with an initial 2-stage Dose Escalation Phase followed by a Dose Expansion Phase.
- Trial name
- NCT06458712
- Testing
- DSB2455
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 180 people
- Sponsor
- Duke Street Bio Ltd
Neoplasms, Unknown Primary
Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP)
The aim of the study is in cancer of unknown primary (CUP) patients, to compare the cost-effectiveness of miRview™ mets test with conventional work-up in identifying the primary tumor site.
- Trial name
- NCT01202786
- Where
- 3 sites in Israel
- Volunteers
- 60 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.